Key result
TAVR links to lower mortality versus conservative management in severe AS and liver cirrhosis.
Why the study?
Risk calculators may deem patients with liver cirrhosis ineligible for TAVR despite potential mortality benefits from the procedure.
Does TAVR decrease mortality risk in patients with severe aortic stenosis and liver cirrhosis compared to not performing TAVR?
Observational
Does TAVR decrease mortality risk in patients with severe aortic stenosis and liver cirrhosis compared to not performing TAVR?
TAVR may offer a mortality benefit over conservative management in patients with severe aortic stenosis and concurrent liver cirrhosis, a population often deemed ineligible for surgical intervention.
Hypothesis-generating for TAVR benefit in severe AS with cirrhosis; prospective trials needed before clinical adoption.
Risk calculators used to predict unfavorable surgical outcomes could flag a patient as ineligible for transcatheter aortic valve replacement (TAVR) based on the presence of liver cirrhosis. Our data analysis suggests that performing a TAVR to treat severe aortic stenosis in patients with liver cirrhosis could decrease their mortality risk as opposed to not performing a TAVR. Careful consideration should be given to this patient population to ensure the best quality of life and long-term outcome.
No takes yet. Share an insight, caveat, or question.
Annie et al. (2023) conducted an observational in Severe aortic stenosis and liver cirrhosis. Transcatheter aortic valve replacement (TAVR) vs. Not performing a TAVR was evaluated on Mortality risk. Performing TAVR in patients with severe aortic stenosis and liver cirrhosis could decrease mortality risk compared to not performing TAVR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: